Searchable abstracts of presentations at key conferences in endocrinology

ea0016p127 | Clinical cases | ECE2008

Is metoclopramide test useful in differentiation of the clinical form of hyperprolactinemia?

Jaskiewicz Katarzyna , Kunert-Radek Jolanta , Pawlikowski Marek

Metoclopramide (MCP) is a selective blocker of dopamine D2 receptor, responsible for the dopamine inhibition of prolactin (PRL) secretion from the pituitary. In normal conditions, administration of the proper dose of MCP leads to increase of PRL concentration in the blood serum. This response was applied in the diagnostic test (MCP test), useful to differentiate between hyperprolactinaemia linked with organic causes (prolactinoma and other lesions of hypothalamo-pituitary regi...

ea0014p158 | (1) | ECE2007

Immunohistochemical detection of angiotensin receptors AT1 and AT2 in adrenal tumors

Pawlikowski Marek , led Beata , Winczyk Katarzyna

Immunohistochemical detection of angiotensin receptors AT1 and AT2 in adrenal tumorsAngiotensin II is well known to affect the adrenal cell growth and function. Angiotensin receptors AT1 and AT2 were found to be present in the normal adrenal gland. However, the data on the expression of angiotensin receptors in the adrenal tumors is very scarce.To overcome this gap, the paraffin sections of the adrenal cortical tumors and of pheoch...

ea0035p1097 | Thyroid Cancer | ECE2014

Do the poorly differentiated and undifferentiated thyroid carcinomas could be the next candidates to somatostatin analoques treatment?

Pisarek Hanna , Pawlikowski Marek , Marchlewska Magdalena , Minias Radoslaw , Winczyk Katarzyna

Introduction: The multimodal management of poorly differentiated thyroid carcinomas (PDTC) and anaplastic carcinomas (ATC) include surgical thyroidectomy, radioiodine treatment, and cytotoxic chemotherapy. Patients with distant metastases which do not respond to radiotherapy could be treated with new therapeutic possibilities like tyrosine kinase inhibitors. PPARγ or mutant P53 are also candidates to PDTC and ATC treatment. Somatostatin and its analogs, demonstrate antipr...

ea0014p144 | (1) | ECE2007

Angiotensin 4–8 and angiotensin 5–8 inhibit cell proliferation in GH3 rat pituitary lactosomatotroph tumor cell culture

Ptasinska-Wnuk Dorota , Kunert-Radek Jolanta , Lawnicka Hanna , Pawlikowski Marek

Introduction: In many tissues angiotensin peptides acts as the auto/paracrine growth factors. Their effects are dependent on activation of various intracellular signaling pathways, including mitogen-activated protein kinases (MAPK).Angiotensin II (ang II) is the best known angiotensin peptide. The ang II derivatives, angiotensin III (ang III) and angiotensin IV (ang IV) posses biological activity as well. Both ang II and ang IV are known to promote the p...

ea0037ep719 | Pituitary: clinical | ECE2015

Somatostatin analogues effectiveness in non-functioning pituitary adenomas in comparison with acromegaly

Kunert-Radek Jolanta , Zawada Natalia Bozena , Pawlikowski Marek , Pisarek Hanna , Radek Maciej

Introduction: Somatostatin analogues (SSAs) are used in the treatment of somatotropinomas. Actually, the use of these drugs in clinically non-functioning pituitary adenomas (NFPA) is raised. The aim of the study is to assess the effectiveness of SSA therapy in both groups.Materials and methods: 40 acromegalic patients and 22 patients with NFPA were treated with SSA for the total therapy duration up to 10 years. Hormonal profile, dynamics of tumour size c...

ea0035p560 | Endocrine tumours and neoplasia | ECE2014

Expression of FSH hormone receptors in pituitary adenomas: a marker of tumour aggressiveness?

Pawlikowski Marek , Kunert-Radek Jolanta , Jaranowska Maria , Radek Maciej , Swietoslawski Jacek , Winczyk Katarzyna

Background: In our earlier study we found that pituitary adenomas, like other human tumours, express ectopically follicle stimulating hormone receptors FSH in intratumoral blood vessels endothelia and/or tumoral cells. The aim of the present paper is to provide the more detailed data on FSHR expression in different subtypes of pituitary adenomas and to evaluate its possible role as a prognostic and/or predictive biomarker in these tumours.Material and me...

ea0014p160 | (1) | ECE2007

Inhibitory effect of rosiglitazone – PPARgamma receptor ligand on growth of human adrenocortical tumor cells in vitro

Winczyk Katarzyna , Lawnicka Hanna , Fuss-Chmielewska Julita , Kolomecki Krzysztof , Kuroszczyk Jacek , Pawlikowski Marek

Introduction: The peroxisome proliferator-activated receptors gamma (PPARγ) are nuclear receptors which are detected in normal and pathological tissues. Our earlier study showed the overexpression of PPARγ in human adrenal tumors and pituitary adenomas in comparison to normal glands. The in vitro experiments indicated that ligands of PPARγ inhibit growth of many tumors including pituitary adenomas, thyroid cancers and adrenal carcinomas. However, the data...